retatrutide mechanism triple agonist glp-1 gip glucagon The power of three: Retatrutide's role in modern obesity and diabetes therapy First Retatrutide phase 3 data,

Observational Studies on GLP-1R Agonists and Substance Use Outcomes The clinical potential of GLP-1RAs in modulating substance use behaviors has been increasingly recognized through preclinical and early translational studies

In conclusion, it is essential to strategically use both GLP-1RA and SGLT2i for cardiovascular prevention in ASCVD patients with type 2 diabetes by targeting HbA1c levels and achieving blood pressure control (Fig

The objective of this review is to summarize the main renal outcomes from clinical studies while providing practical guidance on the use of GLP-1 RAs

The following is a review of the preclinical and clinical studies examining the role of GLP-1R agonists on the vascular endothelium and HFpEF: Data from preclinical studies In a study on non-diabetic mice models with arterial hypertension (simulating preconditions for HFpEF), Liraglutide treatment improved blood pressure and cardiac hypertrophy in angiotensin II-induced arterial hypertension independent of glucose/insulin modulation leading to the reversal of cardiac hypertrophy

Does gastric sleeve work better long term than GLP-1 medications

It reduces appetite by targeting brain areas that control hunger, slows gastric emptying to extend feelings of fullness, and improves insulin sensitivity